Paget's disease of bone: Reduction of disease activity with oral risedronate

Bone

Volumn 22, Issue 1, 1998, Pages 51-55

  Hosking, D J ^a   Eusebio, R A ^b   Chines, A A ^b  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Alkaline phosphatase; Bisphosphonate, bone; Hydroxyproline; Paget's disease; Pain; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CREATININE; HYDROXYPROLINE; PHOSPHATE; RISEDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE PAIN; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYDROXYPROLINE URINE LEVEL; MALE; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; PHOSPHATE BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CHANNEL BLOCKERS; ETIDRONIC ACID; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PAIN; PHOSPHATES; TREATMENT OUTCOME;

EID: 0031972973     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(97)00222-6     Document Type: Article

References (21)

1. Altman R. D., Johnston C. C., Khairi M. R. A., Wellman H., Serafini A. N., Sankey R. R. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med. 289:1973;1379-1384.
2. Audran M., Clochon P., Ethgen D., Mazieres B., Renier J. C. Treatment of Paget's disease of bone with (4-chloro-phenyl) thiomethylene bisphosphonate. Clin Rheumatol. 8:1989;71-79.
3. Brown J. P., Kylstra J. W., Bekker P. J., Axelrod D. W., Siris E. S., Altman R. D., Singer F. R. Risedronate in Paget's disease Preliminary results of a multicenter study . Semin Arthrit Rheum. 23:1994;272.
4. Geddes A. D., D'Souza S. M., Ebetino F. H., Ibbotson K. J. Bisphosphonates Structure-activity relationships and therapeutic implications . Heersche J. N. M., Kanis J. A. Bone and Mineral Research. 1994;265-306 Elsevier, New York.
5. Gray R. E. S., Yates A. J., Preston C. J., Smith R., Russell R. G. G., Kanis J. A. Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med. 245:1987;755-767.
6. Hosking D. J. Calcitonin and diphosphonate in the treatment of Paget's disease of bone. Metab Bone Dis Relat Res. 3:1981;317-326.
7. Kanis J. A. Pathophysiology and treatment of Paget's disease of bone. Fogelman I. Metabolic Bone Disease. 1991;Carolina Academics/Dunitz, London.
8. Khairi M. R. A., Altman R. D., DeRosa G. P., Zimmermann J., Schenk R. K., Johnston C. C. Sodium etidronate in the treatment of Paget's disease of bone A study of long-term results . Ann Intern Med. 87:1977;656-663.
9. Kylstra J. W., Bekker P. J., Clemens T. L., Valentin-Opran A., Axelrod D. W., Singer F. R. Risedronate in resistant Paget's disease of bone. Bone Miner. 17:(Suppl. 1):1992;S209.
10. McClung M. R., Tou C. K. P., Goldstein N. H., Picot C. Tiludronate therapy in Paget's disease of bone. Bone. 17:(Suppl.):1995;S493-S496.
11. McOsker, J. Preclinical pharmacology of risedronate, a 3rd generation bisphosphonate. In: The 5th International Symposium on Bone, Structure, Function and Disease, Sydney, Australia, April 23-25, 1990; abstract.
12. Reasner C. A., Stone M. D., Hosking D. J., Ballah A., Mundy G. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab. 77:1993;1067-1071.
13. Reginster J. Y., Jeugmans-Huynen A. M., Albert A., Denis D., Deroisy R., Lecart M. P., Fontaine M. A., Collette J., Franchimont P. Biological and clinical assessment of a new bisphosphonate (chloro-4-phenyl) thiomethylene bisphosphonate, in treatment of Paget's disease of bone. Bone. 9:1988;349-354.
14. Reginster J. Y., Lecort M. P., Deroisy R., Ethgen D., Zegels B., Franchimont P. Paget's disease of bone treated with five day course of oral tiludronate. Ann Rheum Dis. 52:1993;54-57.
15. Roux C., Gennari C., Farrerons J., Devogelaer J. P., Mulder H., Kruse H. P., Picot C., Titeux L., Reginster J. Y., Dougados M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthrit Rheum. 38:1995;851-858.
16. Roux C., Ravaud M., Cohen-Solal M. C., DeVernejoul M. C., Guillemant S., Cherruau Delmas P., Dougados M., Amor B. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone. 15:1994;41-49.
17. Sietsema W. K., Ebetino F. H., Salvagno A. M., Bevan J. A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:1989;389-396.
18. Singer F. R., Krane S. M. Paget's disease of bone. Avioli L. V., Krane S. M. Metabolic Bone Disease and Clinically Related Disorders. 1990;546-615 Saunders, Philadelphia.
19. Siris E., Weinstein R. S., Altman R., Conte J. M., Favus M., Lombardi A., Lyles K., McIlwain H., Murphy W. H., Reda C., Rude M., Seton M., Tiegs R., Thompson D., Tucci J. R., Yates A. J., Zimering M. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 81:1996;961-967.
20. Stone M. D., Hawthorne A. B., Kerr D., Webster G., Hosking D. J. Treatment of Paget's disease with intermittent low-dose infusion of disodium pamidronate (APD). J Bone Miner Res. 5:1990;1231-1235.
21. Walton R. J., Russell R. G. G., Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate in man. Clin Sci Mol Med. 49:1975;45-56.